<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
<journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
<journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
<journal-title-group>
<journal-title>JCI Insight</journal-title>
</journal-title-group>
<issn pub-type="epub">2379-3708</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31990683</article-id>
<article-id pub-id-type="pmc">7101145</article-id>
<article-id pub-id-type="publisher-id">132094</article-id>
<article-id pub-id-type="doi">10.1172/jci.insight.132094</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rescuing compounds for Lesch-Nyhan disease identified using stem cell–based phenotypic screening</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ruillier</surname>
<given-names>Valentin</given-names>
</name>
<email>val.ruillier@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0696-1307</contrib-id>
<name>
<surname>Tournois</surname>
<given-names>Johana</given-names>
</name>
<email>jtournois@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boissart</surname>
<given-names>Claire</given-names>
</name>
<email>cboissart@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lasbareilles</surname>
<given-names>Marie</given-names>
</name>
<email>mlasbareilles@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mahé</surname>
<given-names>Gurvan</given-names>
</name>
<email>gurvan.mahe987@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9180-2794</contrib-id>
<name>
<surname>Chatrousse</surname>
<given-names>Laure</given-names>
</name>
<email>lchatrousse@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8937-9875</contrib-id>
<name>
<surname>Cailleret</surname>
<given-names>Michel</given-names>
</name>
<email>mcailleret@istem.fr</email>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9966-3282</contrib-id>
<name>
<surname>Peschanski</surname>
<given-names>Marc</given-names>
</name>
<email>mpeschanski@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Benchoua</surname>
<given-names>Alexandra</given-names>
</name>
<email>abenchoua@istem.fr</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>CECS ,</aff>
<aff id="A2"><label>2</label>INSERM UMR 861, and</aff>
<aff id="A3"><label>3</label>UEVE UMR 861, I-Stem, AFM-Téléthon, Corbeil-Essonnes, France.</aff>
<author-notes>
<corresp>Address correspondence to: Alexandra Benchoua, CECS/I-Stem, 28 rue Henri Desbruère-91100, Corbeil-Essonnes, France. Phone: 33.1.69.90.85.87; Email: <email>abenchoua@istem.fr</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2020-02-27T09:00:00-0500" publication-format="electronic">
<day>27</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2020-02-27T09:00:00-0500" publication-format="electronic">
<day>27</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>2</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>4</issue>
<elocation-id>e132094</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 American Society for Clinical Investigation</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://insight.jci.org/articles/view/132094">This article is available online at https://insight.jci.org/articles/view/132094</self-uri>
<abstract>
<p>Lesch-Nyhan disease (LND) is a rare monogenic disease caused by deficiency of the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). LND is characterized by severe neuropsychiatric symptoms that currently cannot be treated. Predictive in vivo models are lacking for screening and evaluating candidate drugs because LND-associated neurological symptoms are not recapitulated in HGPRT-deficient animals. Here, we used human neural stem cells and neurons derived from induced pluripotent stem cells (iPSCs) of children affected with LND to identify neural phenotypes of interest associated with HGPRT deficiency to develop a target-agnostic–based drug screening system. We screened more than 3000 molecules and identified 6 pharmacological compounds, all possessing an adenosine moiety, that corrected HGPRT deficiency–associated neuronal phenotypes by promoting metabolism compensations in an HGPRT-independent manner. This included <italic>S</italic>-adenosylmethionine, a compound that had already been used as a compassionate approach to ease the neuropsychiatric symptoms in LND. Interestingly, these compounds compensate abnormal metabolism in a manner complementary to the gold standard allopurinol and can be provided to patients with LND via simple food supplementation. This experimental paradigm can be easily adapted to other metabolic disorders affecting normal brain development and functioning in the absence of a relevant animal model.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<graphic orientation="portrait" position="float" xlink:href="jciinsight-5-132094-g150.jpg"></graphic>
</p>
</abstract>
<abstract abstract-type="toc">
<p>Human neural stem cells and neurons derived from iPSCs of Lesch-Nyhan disease patients were used to develop a target-agnostic-based drug screening system.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Stem cells</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Drug screens</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>French National Research Agency (ANR)</funding-source>
<award-id>ANR-11-INBS-0009,and,ANR-11-INBS-0011</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>